Navigation Links
Covance Board Authorizes $250 Million Stock Buyback
Date:9/28/2010

PRINCETON, N.J., Sept. 28 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) said today that its Board of Directors has authorized the repurchase of up to $250 million of its outstanding common stock. This authorization is in addition to the approximately 800,000 shares remaining under the repurchase authorization announced in 2007 and currently represents nearly ten percent of the Company's common stock. Any purchases under this buyback would be dependent upon business and market conditions and other factors. The stock purchases may be made from time to time and may be made through a variety of methods including open market purchases, privately negotiated transactions, block trades, and 10b5-1 plans.

"This action reflects the confidence of the Board and management in the fundamental strengths and future outlook of Covance," said Joe Herring, Chairman and Chief Executive Officer of Covance.

About Covance

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.8 billion, global operations in more than 30 countries, and more than 10,000 employees worldwide.  Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Statements contained in this press release, which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, risks associated with acquisitions and investments, and the Company's ability to increase order volume, the pace of translation of orders into revenue in late-stage development services, and other factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no duty to update any forward looking statement to conform the statement to actual results or changes in the Company's expectations.


'/>"/>
SOURCE Covance Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies
2. Covance Receives Highest Level of Phase I Accreditation
3. Covance Inc. Invites You to Join the Webcast of Its Fourth Quarter 2009 Financial Results Conference Call
4. Covance to Present at the 28th Annual J.P. Morgan Healthcare Conference
5. Rules-Based Medicine Forms Biomarker Alliance With Covance Inc.
6. Covance Enters Into a Biomarker Alliance With Rules-Based Medicine, Inc.
7. Covance to Present at Piper Jaffray 21st Annual Health Care Conference
8. Covance To Present At The 20th Annual Global Healthcare Services Conference
9. Covance To Present at the Deutsche Bank 35th Annual Health Care Conference
10. Covance to Present at Goldman Sachs 31st Annual Global Healthcare Conference
11. Covance to Present at William Blair & Companys 30th Annual Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2017)... Calif. , June 9, 2017 AirXpanders, ... company focused on the design, manufacture, sale and distribution ... market on the progress of its commercial roll-out in ... now available in more than one hundred (100) medical ... AeroForm offers a needle-free alternative for women ...
(Date:6/7/2017)... , June 7, 2017 Endo International plc ... 7, 2017, the Hon. Joseph R. Goodwin , ... West Virginia , entered a case ... Pelvic Repair System Products Liability Litigation (the "MDL") that ... cases to provide expert disclosures on specific causation within ...
(Date:6/3/2017)... 3, 2017  Eli Lilly and Company (NYSE: ... from the Phase 3 MONARCH 2 study showed ... inhibitor, in combination with fulvestrant, significantly improved progression-free ... in women with hormone-receptor-positive (HR+), human epidermal growth ... have relapsed or progressed after endocrine therapy (median ...
Breaking Medicine Technology:
(Date:6/25/2017)... ... June 25, 2017 , ... CareSet Labs released the Root NPI ... This is a new, greatly improved version of the Doctor Referral teaming dataset commonly ... Fred Trotter and subsequently called the the “Doctor Referral Dataset” as released by Medicare ...
(Date:6/24/2017)... ... June 24, 2017 , ... Genes Advice, a new company ... Florida and Texas doctors' offices and clinics. This breakthrough testing is part of ... recognizes the role genes play in determining an individual's tolerance of and reaction ...
(Date:6/24/2017)... ... , ... The weather is heating up and the days are getting longer, ... aware that the summer months provide more than warmer temperatures that are perfect for ... negatively affected from direct exposure to the sun. When it comes to the security ...
(Date:6/23/2017)... ... June 23, 2017 , ... "The Better Care Reconciliation Act ... harm to people with all chronic conditions, including mental illnesses, while increasing the ... the Affordable Care Act (ACA) requirement that insurers cover pre-existing conditions, it does ...
(Date:6/23/2017)... ... 24, 2017 , ... Studies show evidence that carotenoids and antioxidants derived either ... in these patients. , But how often do ophthalmologists and optometrists in Sweden recommend ... risk of or with early symptoms of AMD? A study published recently ...
Breaking Medicine News(10 mins):